Perspective of a pre‐symptomatic individual with an FTD‐causing MAPT gene variant

Every living generation of my family has been affected by early-onset genetic FTD. The disease is caused by the V337M MAPT mutation, an autosomal dominant gene variant that leads to onset of behavioral symptoms in carrier individuals between the ages of 35 and 50. My mother and five of her eight siblings have developed symptoms which have caused tremendous hardship and heartache for our family. I was tested for V337M and I learned that I am also a carrier of the variant. This information has been a heavy burden for me to bear and has guided my decisions about how I spend my healthy years and my decision not to have biological children. The knowledge that I and many of my young relatives will be affected by FTD in the future has galvanized me to become an advocate for MAPT families. Fear and social stigma often prevent at-risk individuals from getting tested, participating in research and telling our stories. When we support each other and advocate for our needs we pave the way for development of transformative new therapies for genetic FTD.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-12-01
DOI
https://doi.org/10.1002/alz70858_102304
Primary Topic
Genomics and Rare Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Perspective of a pre‐symptomatic individual with an FTD‐causing MAPT gene variant

Ansel Dow
Alzheimer s & Dementia
Genomics and Rare Diseases
article

Perspective of a pre‐symptomatic individual with an FTD‐causing MAPT gene variant

Ansel Dow
article en

Abstract

Every living generation of my family has been affected by early-onset genetic FTD. The disease is caused by the V337M MAPT mutation, an autosomal dominant gene variant that leads to onset of behavioral symptoms in carrier individuals between the ages of 35 and 50. My mother and five of her eight siblings have developed symptoms which have caused tremendous hardship and heartache for our family. I was tested for V337M and I learned that I am also a carrier of the variant. This information has been a heavy burden for me to bear and has guided my decisions about how I spend my healthy years and my decision not to have biological children. The knowledge that I and many of my young relatives will be affected by FTD in the future has galvanized me to become an advocate for MAPT families. Fear and social stigma often prevent at-risk individuals from getting tested, participating in research and telling our stories. When we support each other and advocate for our needs we pave the way for development of transformative new therapies for genetic FTD.

Alzheimer s & DementiaVol. 21(S4)
Family Health International 360 (US)
Openalex Percentile: Top 25%
Genomics and Rare Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.